Patent ID: 8415114

Claim:
A method for determining aberrant in vivo a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity in a test subject comprising the step of measuring recombinant von Willebrand Factor (rVWF) cleavage fragments in a blood sample from the test subject after (a) administering rVWF to the test subject, or (b) adding rVWF to the blood sample from the test subject and subjecting the blood sample to shear stress, wherein a change in rVWF cleavage fragment levels in the blood sample of the test subject compared to rVWF cleavage fragment levels in a blood sample from a control subject known to have normal ADAMTS13 activity indicates aberrant in vivo ADAMTS13 activity in the test subject.